Biologics for Systemic Lupus Erythematosus Treatment

Introduction to Biologics

The American College of Rheumatology recommends using belimumab to treat patients with moderate to severe SLE who have inadequate response to standard therapy, defined as residual disease activity preventing glucocorticoid tapering and/or frequent relapses 1, 2

The FDA approves belimumab for patients 5 years and older with active SLE receiving standard therapy, and for active lupus nephritis receiving standard therapy, as stated by the European League Against Rheumatism 1, 2

Belimumab provides a 33% greater likelihood of achieving ≥4-point SLEDAI reduction compared to placebo, with high-certainty evidence showing clinically meaningful improvement in disease activity at 52 weeks, according to the European League Against Rheumatism 2
Belimumab increases the likelihood of reducing glucocorticoid dose by ≥50% by 59%, enabling tapering below 7.5 mg/day prednisone equivalent, as recommended by the American College of Rheumatology 2, 3, 4

For active lupus nephritis, belimumab is recommended as first-line add-on therapy with Grade 1B evidence, as stated by the Kidney Disease: Improving Global Outcomes initiative 5, 2
The BLISS-LN trial demonstrated belimumab achieved primary efficacy renal response in 43% versus 32% with placebo at 2 years, according to the Kidney Disease: Improving Global Outcomes initiative 5

For lupus nephritis, belimumab should be combined with mycophenolate mofetil or low-dose cyclophosphamide, as recommended by the European League Against Rheumatism 5, 2

Belimumab is not recommended for severe active CNS lupus or isolated Class V lupus nephritis, as stated by the American College of Rheumatology 4

Belimumab has been studied for up to 13 years with maintained efficacy and no new safety concerns emerging over time, according to the European League Against Rheumatism 2
Treatment should be continued as long as clinical benefit persists, with optimal duration remaining undefined, as recommended by the American College of Rheumatology 2

Rituximab can be considered off-label for organ-threatening disease refractory to or with intolerance/contraindications to standard immunosuppressive agents, as stated by the European League Against Rheumatism 1, 5